… trial in participants with obesity. The results of our study with once-weekly semaglutide at a
2.4-… once-daily semaglutide at a dose of 0.4 mg than with placebo after 52 weeks of treatment. …

… efficacy and safety of once-weekly semaglutide among adults with overweight or obesity. …
controlled trials that compared once-weekly semaglutide versus placebo in adults with …

… The STEP 8 trial directly compared once-weekly semaglutide, 2.4 mg, vs once-daily liraglutide,
3.0 mg, for weight management in adults with overweight or obesity to rigorously assess …

… the effect of continuing once-weekly treatment with subcutaneous semaglutide, 2.4 mg, vs
… overweight/obesity who reached a semaglutide treatment dosage of 2.4 mg once weekly …

… overweight/obesity, once-weekly semaglutide 2.4 mg and 1.0 mg reduced CRP concentration
irrespective of baseline BMI/… a potential anti-inflammatory role of semaglutide in obesity. …

… with overweight or obesity at a once-weekly subcutaneous dose of 2.4 mg. In the phase III
Semaglutide Treatment Effect in People with obesity (STEP) 1-4 studies, weekly semaglutide …

… Among adults with overweight or obesity, once-weekly treatment with subcutaneous semaglutide
… Semaglutide at a dose of 2.4 mg is approved for long-term weight management as an …

… Semaglutide 2·4 mg once weekly has been investigated for weight management in global
populations. Differences exist between Asian and non-Asian populations in terms of body …

… of once-weekly (OW) subcutaneous semaglutide 2.4 mg vs placebo in adults with
overweight/obesity … Adults with body mass index (BMI) >30 kg/m2, or >27 kg/m2 with >1 …

… once-weekly subcutaneous semaglutide in conjunction with behavioral intervention in adults
with overweight (with at least one weight-related comorbidity) or obesity (without diabetes) …